PHASE I STUDY OF RO6958688 +/- OTHER ANTI-CANCER AGENTS IN PATIENTS WITH ADVANCED SOLID TUMORS

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223708

Enrollment

Registered

2017-11-09

Start date

2017-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Interventions

investigational material(s) Generic name etc : RO6958688 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced or recurrent cancer that is refractory or ineligible to standard therapy or for which no standard therapy exists. Histologically or cytologically confirmed solid tumor. Confirmation of CEA-positivity at the sponsor-designated central laboratory ECOG PS of 0 or 1. Life expectancy >= 12 weeks from the date of enrollment. Major organ function meets all criteria.

Exclusion criteria

Exclusion criteria: Pregnant or lactating woman. Current or previous autoimmune disease. History of adverse drug reactions that were considered to be immune-mediated, or severe as a result of cancer immunotherapy, including immune checkpoint inhibitors. Positive test result for human immunodeficiency virus (HIV) antibody, hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, or hepatitis C virus (HCV) antibody (eligible if HCV-RNA-negative).

Design outcomes

Primary

Measure	Time frame
DLT, AE, PK NCI CTCAE, PK parameter	—

Secondary

Measure	Time frame
Efficacy, ATA RECIST, ATA	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026